1. Membrane Transporter/Ion Channel
  2. SGLT

SGLT

SGLT (Sodium-dependent glucose cotransporters) are a family of glucose transporter found in the intestinal mucosa (enterocytes) of the small intestine (SGLT1) and the proximal tubule of the nephron (SGLT2 in PCT and SGLT1 in PST). SGLT contribute torenal glucose reabsorption. In the kidneys, 100% of the filtered glucose in the glomerulus has to be reabsorbed along the nephron (98% in PCT, via SGLT2). In case of too high plasma glucose concentration (hyperglycemia), glucose is excreted in urine (glucosuria); because SGLT are saturated with the filtered monosaccharide. Glucose is never secreted by the nephron. There are two most well known members of SGLT family are SGLT1 and SGLT2, which are members of the SLC5A gene family. Inhibition of SGLT2 leads to a reduction in blood glucose levels. Therefore, SGLT2 inhibitors have potential use in the treatment of type II diabetes.

SGLT Related Products (15):

Cat. No. Product Name Effect Purity
  • HY-15409
    Empagliflozin Inhibitor
    Empagliflozin is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for hSGLT-2.
  • HY-10451
    Canagliflozin Inhibitor
    Canagliflozin is a selective SGLT2 inhibitor with IC50 of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively.
  • HY-10450
    Dapagliflozin Inhibitor
    Dapagliflozin is a new pharmacological therapy for type 2 diabetes, and inhibits sodium/glucose cotransporter 2 (SGLT2), which results in excretion of glucose into the urine.
  • HY-N0143
    Phlorizin Inhibitor
    Phlorizin is a non-selective SGLT inhibitor with Kis of 300 and 39 nM for hSGLT1 and hSGLT2, respectively. Phlorizin is also a Na+/K+-ATPase inhibitor.
  • HY-N0142
    Phloretin Inhibitor
    Phloretin(NSC 407292; RJC 02792) is a dihydrochalcone, a type of natural phenols. Phloretin inhibits the active transport of glucose into cells by SGLT1 and SGLT2.
  • HY-10449
    Luseogliflozin Inhibitor
    Luseogliflozin is a potent sodium-dependent glucose cotransporter (SGLT) 2 inhibitor, with an IC50 of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC50,3990 nM); Luseogliflozin has the protential for treating type 2 diabetes.
  • HY-109092
    Licogliflozin Inhibitor
    Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor.
  • HY-15516
    LX-4211 Inhibitor
    LX-4211 is a potent dual SGLT2/1 inhibitor; Antidiabetic agents.
  • HY-13413
    Tofogliflozin hydrate Inhibitor
    Tofogliflozin(CSG-452) hydrate is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2.
  • HY-15461
    PF-04971729 Inhibitor
    PF-04971729(Ertugliflozin) is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2(SGLT2).
  • HY-10450A
    Dapagliflozin ((2S)-1,2-propanediol, hydrate) Inhibitor
    Dapagliflozin (2S)-1,2-propanediol, hydrate is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin inhibits sodium/glucose cotransporter 2 (SGLT2), which results in excretion of glucose into the urine.
  • HY-I0383
    Canagliflozin hemihydrate Inhibitor
    Canagliflozin 0.5 H2O(JNJ 28431754; TA 7284) is a highly potent and selective SGLT2 inhibitor for hSGLT2 with IC50 of 2.2 nM, exhibits 413-fold selectivity over hSGLT1.
  • HY-17604
    Bexagliflozin Inhibitor
    Bexagliflozin is a potent and selective SGLT2 inhibitor with IC50 value of 5.6 μM /2 nM in SGLT1 /SGLT2 respectively.
  • HY-14894
    Ipragliflozin Inhibitor
    Ipragliflozin (ASP1941) is a highly potent and selective SGLT2 inhibitor with IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6.
  • HY-14902
    Tofogliflozin Inhibitor
    Tofogliflozin(CSG-452) is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2.